In a filing, Atyr Pharma Inc revealed its Director Gross Jane A acquired Company’s shares for reported $15000.0 on Mar 17 ’25. In the deal valued at $4.00 per share,3,750 shares were bought. As a result of this transaction, Gross Jane A now holds 9,750 shares worth roughly $9847.5.
Then, Broadfoot Jill Marie sold 1,254 shares, generating $4,740 in total proceeds. Upon selling the shares at $3.78, the Chief Financial Officer now owns 31,763 shares.
Before that, DENYES NANCY sold 899 shares. Atyr Pharma Inc shares valued at $3,398 were divested by the General Counsel at a price of $3.78 per share. As a result of the transaction, DENYES NANCY now holds 26,555 shares, worth roughly $26820.55.
Wells Fargo downgraded its Atyr Pharma Inc [ATYR] rating to an Equal weight from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who decreased its forecast for the stock in mid September from “an Outperform” to “a Market perform”. H.C. Wainwright also remained covering ATYR and has decreased its forecast on September 15, 2025 with a “Neutral” recommendation from previously “Buy” rating. Cantor Fitzgerald revised its rating on September 15, 2025. It rated ATYR as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of ATYR
On Monday, Atyr Pharma Inc [NASDAQ:ATYR] saw its stock fall -83.17% to $1.01. Over the last five days, the stock has lost -81.41%. Atyr Pharma Inc shares have fallen nearly -46.30% since the year began. Nevertheless, the stocks have fallen -71.96% over the past one year.
How much short interest is there in Atyr Pharma Inc?
A steep rise in short interest was recorded in Atyr Pharma Inc stocks on 2025-08-29, growing by 3.81 million shares to a total of 29.41 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 25.6 million shares. There was a rise of 12.95%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 18, 2025 when Leerink Partners began covering the stock and recommended ‘”an Outperform”‘ rating along with a $16 price target.
